alzheimersnewstoday4d
Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...
alzheimersnewstoday4d
Experimental Treatments for Alzheimer’s Disease
The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...
alzheimersnewstoday4d
Experimental Treatments That Target Beta-Amyloid Protein
One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of so-called beta-amyloid fragments that stick together and accumulate ...